U.S. pharma giant copyright scrapped two experimental weight loss tablets final year—a as soon as-everyday capsule, lotiglipron, resulting from elevated liver enzymes plus a two times-everyday capsule, danuglipron, because of strong Unwanted effects—but CEO Albert Bourla has stated the company is determined to “Engage in and acquire” while